Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

20.04B

Market cap20.04B

Price-Earnings ratio

14.19

Price-Earnings ratio14.19

Dividend yield

—

Dividend yield—

Average volume

1.52M

Average volume1.52M

High today

—

High today—

Low today

—

Low today—

Open price

$99.12

Open price$99.12

Volume

0.00

Volume0.00

52 Week high

$112.29

52 Week high$112.29

52 Week low

$59.15

52 Week low$59.15

Stock Snapshot

The current Incyte(INCY) stock price is $98.97, with a market capitalization of 20.04B. The stock trades at a price-to-earnings (P/E) ratio of 14.19.

On 2026-05-12, Incyte(INCY) stock opened at $99.12, reached a high of —, and a low of —.

The Incyte(INCY)'s current trading volume is 0, compared to an average daily volume of 1.52M.

During the past year, Incyte(INCY) stock moved between $59.15 at its lowest and $112.29 at its peak.

INCY News

Simply Wall St 2d

Impressive Earnings May Not Tell The Whole Story For Incyte

Incyte Corporation ( ) announced strong profits, but the stock was stagnant. We did some digging, and we found some concerning factors in the details. Advertis...

Simply Wall St 4d

Assessing Incyte Valuation After FDA Wins For Jakafi XR Opzelura And Pancreatic Cancer Therapy

Incyte (INCY) stock is in focus after the US FDA approved once daily Jakafi XR, along with positive Phase 3 Opzelura data in atopic dermatitis and orphan drug d...

TipRanks 4d

Incyte Targets KRAS G12D Pancreatic Cancer With New Phase 3 DAWN-303 Trial

Incyte (INCY) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Di...

Analyst ratings

52%

of 29 ratings

Buy

37.9%

Hold

51.7%

Sell

10.3%

More INCY News

TipRanks 5d

Incyte announces 24-week long-term data from Phase 3 TRuE-AD4 trial

Incyte (INCY) announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura cream in adults with moderate atopic d...

Simply Wall St 5d

The Bull Case For Incyte Could Change Following FDA Approval Of Once-Daily Jakafi XR

In early May 2026, Incyte received U.S. FDA approval for Jakafi XR, a once-daily extended-release ruxolitinib tablet for multiple hematologic and graft-versus-h...

Simply Wall St 6d

Jakafi XR Approval Tests Incyte Valuation As Growth Outlook Softens

FDA approves Jakafi XR extended-release tablets for myelofibrosis, polycythemia vera and graft-versus-host disease. Jakafi XR offers a once-daily dosing option...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Credo Technology Group

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.